CoLucid Pharmaceuticals Inc

Type: Company
Name: CoLucid Pharmaceuticals Inc
First reported May 23 2014 - Updated May 23 2014 - 2 reports

Research and Markets: Lasmiditan by CoLucid Pharmaceuticals Under Licensing Agreement With Ali Lilly - Forecast and Market Analysis to 2023

DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/vrg994/lasmiditan) has announced the addition of the "Lasmiditan (Migraine) - Forecast and Market Analysis to 2023" report to their offering. CoLucid Pharmaceuticals ... [Published Business Wire Professional Services News - May 23 2014]
First reported May 06 2014 - Updated May 06 2014 - 1 reports

CoLucid Pharmaceuticals, Inc., Announces Agreement from the FDA on a Special Protocol Assessment (SPA) for the Phase 3 Trial of Lasmiditan in Migraine Including Patients with Risk Factors for Cardiovascular Disease

DURHAM, N.C., May 6, 2014 /PRNewswire/ -- CoLucid Pharmaceuticals, Inc., a privately held biopharmaceutical company, has reached agreement with the U.S. Food and Drug Administration (FDA) for the planned SAMURAI study.  The objective of this trial is ... [Published PR Newswire: Health - May 06 2014]

More Content

All (3) | News (0) | Reports (0) | Blogs (3) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
Research and Markets: Lasmiditan by CoLucid Pha... [Published Business Wire Professional Services News - May 23 2014]
Research and Markets: Lasmiditan by CoLucid Pha... [Published Business Wire Health News - May 23 2014]
CoLucid Pharmaceuticals, Inc., Announces Agreem... [Published PR Newswire: Health - May 06 2014]
1
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Research and Markets: Lasmiditan by CoLucid Pha... [Published Business Wire Professional Services News - May 23 2014]
DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/vrg994/lasmiditan) has announced the addition of the "Lasmiditan (Migraine) - Forecast and Market Analysis to 2023" report to their offering. CoLucid Pharmaceuticals ...
Research and Markets: Lasmiditan by CoLucid Pha... [Published Business Wire Health News - May 23 2014]
DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/vrg994/lasmiditan) has announced the addition of the "Lasmiditan (Migraine) - Forecast and Market Analysis to 2023" report to their offering. CoLucid Pharmaceuticals ...
CoLucid Pharmaceuticals, Inc., Announces Agreem... [Published PR Newswire: Health - May 06 2014]
DURHAM, N.C., May 6, 2014 /PRNewswire/ -- CoLucid Pharmaceuticals, Inc., a privately held biopharmaceutical company, has reached agreement with the U.S. Food and Drug Administration (FDA) for the planned SAMURAI study.  The objective of this trial is ...
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.